- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
-
ICON CEO on PRA deal: Groundwork laid for faster trials (Radio)
A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
-
ICON to acquire PRA for $12B as COVID-19 spurs CRO consolidation
ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, in a deal that continues the consolidation of contract research organisations into a handful of corporate giants.
-
ICON to acquire PRA Health Sciences in $12b deal
The deal consolidates two significant players in the contract research organisation arena, in a deal worth approximately $12b USD.
-
-
Breakfast Business (6.30am show, 13:44 mark)
An interview with ICON CFO Brendan Brennan on ICON’s $12B acquisition of PRA Health Sciences.
-
COVID researchers ICON, PRA Health join in $12 billion deal
ICON agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
-
ICON eyes growing virtual clinical trial market with $12 billion PRA Health deal
ICON will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.
-
ICON to buy clinical trial rival PRA in $12 billion deal
In acquiring PRA, ICON would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.
-
Dublin clinical trials group ICON buys PRA in $12bn deal
The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.